Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA | Zendy

Michelle M. O’Shaughnessy | Zendy; Maria E. MontezRath | Zendy; Richard A. Lafayette | Zendy; Wolfgang C. Winkelmayer­ | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA

Author(s) -

Michelle M. O’Shaughnessy,

Maria E. MontezRath,

Richard A. Lafayette,

Wolfgang C. Winkelmayer

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv386

Subject(s) - medicine , hemodialysis , peritoneal dialysis , end stage renal disease , transplantation , gastroenterology , dialysis , focal segmental glomerulosclerosis , lupus nephritis , kidney transplantation , nephropathy , membranoproliferative glomerulonephritis , odds ratio , kidney disease , glomerulonephritis , disease , kidney , diabetes mellitus , endocrinology

Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), while peritoneal dialysis affords certain benefits over hemodialysis. Distributions and determinants of first ESRD treatment modality have not been compared across glomerulonephritis (GN) subtypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research